Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.79 |
| ▸ | HTR1A | P08908 | 2/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425260 | 1.00 | HTR2A (1.00) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL398580 | 1.00 | HTR2A (1.00) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL30341559 | 0.98 | HTR2A (0.96) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5308098 | 0.90 | HTR2A (0.81) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5308097 | 0.90 | HTR2A (0.81) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL2556573 | 0.89 | HTR2A (0.80) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5302329 | 0.89 | HTR2A (0.80) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL2556577 | 0.89 | HTR2A (0.80) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL29633045 | 0.89 | HTR2A (0.80) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5302319 | 0.89 | HTR2A (0.80) | HTR2ATAAR1HTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | claimed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | claimed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | claimed |
| EP-2835648-B1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | RANDOX LABORATORIES LTD (GB) | 2018-12-12 | — | — | EP | claimed |
| EP-2835648-A1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | Randox Laboratories Ltd. (GB) | 2015-02-11 | — | — | EP | claimed |
| US-20150038366-A1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | NORTHERN BANK LIMITED (IE) | 2015-02-05 | — | — | US | claimed |
| US-8163701-B2 | Prodrugs of active agents | SIGNATURE THERAPEUTICS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| US-8101661-B2 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | KEMPHARM, INC. (US) | 2012-01-24 | — | — | US | claimed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | claimed |
| EP-1928881-A2 | PRODRUGS OF ACTIVE AGENTS | Pharmacofore, Inc. (US) | 2008-06-11 | — | — | EP | claimed |
| US-20070123468-A1 | Prodrugs of active agents | PHARMACOFORE, INC. | 2007-05-31 | — | — | US | claimed |
| WO-2007022535-A2 | PRODRUGS OF ACTIVE AGENTS | PHARMACOFORE, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-5470997-A | Amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0634999-A4 | NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS. | — | 1995-02-01 | — | — | EP | disclosed |
| EP-0634999-A1 | NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS | BIOSITE DIAGNOSTICS INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993020048-A1 | NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885TAAR1 128/4885HTR1A 13/4885 |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 7/4885TAAR1 181/4885HTR1A 12/4885 |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC18A2, SLC6A19, SLC6A2 | HTR2A 83/4885TAAR1 72/4885HTR1A 68/4885 |
| US-20150038366-A1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | PNMT, DDT, COMT | HTR2A 71/4885TAAR1 514/4885HTR1A 210/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | HTR2A 2491/4885TAAR1 543/4885HTR1A 1360/4885 |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885TAAR1 128/4885HTR1A 13/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 9/4885TAAR1 121/4885HTR1A 11/4885 |
| US-20070123468-A1 | Prodrugs of active agents | PAICS, AADAC, NQO1 | HTR2A 2342/4885TAAR1 3066/4885HTR1A 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.